ABBV-318 CAS No.: 1802848-94-7

for this product.

Introduction:

As a leading Chinese manufacturer of high-quality biochemical products, we are proud to present our latest innovation to the global market – ABBV-318. This product is a novel and highly potent inhibitor of the Interleukin-7 receptor (IL-7R) signaling pathway, which has been shown to have promising therapeutic potential in a variety of diseases, including cancer and autoimmune disorders. In this product introduction, we will delve deeper into the scientific aspects of this compound, as well as its potential applications and commercial value.

Scientific Background:

The Interleukin-7 receptor (IL-7R) is a transmembrane protein that is expressed on the surface of various cells in the immune system, including T cells and B cells. The binding of IL-7 to its receptor activates a signaling pathway that plays a crucial role in the survival, proliferation, and differentiation of these cells. However, aberrant signaling through this pathway has been implicated in the development and progression of several diseases, including cancer and autoimmune disorders.

ABBV-318 is a small molecule inhibitor that selectively targets the IL-7R signaling pathway by binding to the extracellular domain of the receptor. This prevents the binding of IL-7 and blocks downstream signaling events, leading to inhibition of cell growth and survival. In preclinical studies, ABBV-318 has demonstrated potent antitumor activity against various types of cancer, including leukemia, lymphoma, and solid tumors. Additionally, it has shown efficacy in several autoimmune disease models, suggesting its potential as a therapeutic agent for these conditions.

Potential Applications:

Due to its broad activity profile and excellent pharmacological properties, ABBV-318 has the potential to be developed into a novel therapeutic agent for a variety of diseases. Some of its potential applications include:

1. Cancer: ABBV-318 has shown potent antitumor activity against various types of cancer in preclinical studies. Its mechanism of action makes it an attractive candidate for combination therapy with other anticancer agents, as it may enhance their efficacy.

2. Autoimmune disorders: The IL-7R signaling pathway has been implicated in the pathogenesis of several autoimmune disorders, including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. ABBV-318 has shown efficacy in several animal models of these diseases, demonstrating its potential as a novel therapeutic agent.

3. Immunotherapy: Given its ability to selectively target the IL-7R signaling pathway, ABBV-318 may have applications in immunotherapy, particularly in combination with immune checkpoint inhibitors.

Commercial Value:

As a manufacturer of fine chemical products, we can see that ABBV-318 has significant commercial potential, both in terms of its therapeutic value and market demand. Oncology is a field with huge unmet medical needs and continues to grow year by year. With the favorable preclinical study results, ABBV-318 may have a good chance of becoming a new drug candidate for cancer treatment. According to our recent market research, the global anticancer drug market is expected to reach a value of 156.57 billion by 2023. Furthermore, with the growing incidence of autoimmune disorders worldwide, there is an increasing need for new and effective therapies in this area. The global autoimmune disease treatment market is projected to reach a value of 153.32 billion by 2026. We believe that ABBV-318 has the potential to capture a significant share of these markets.

Conclusion:

ABBV-318 is a highly promising small molecule inhibitor with potent activity against the IL-7R signaling pathway. Its potential applications in oncology, autoimmune disorders, and immunotherapy make it an attractive candidate for further development as a novel therapeutic agent. As a Chinese manufacturer, we are committed to providing high-quality products and services to customers worldwide, and we are confident that ABBV-318 will be of great value to our clients and partners.

Chemical Structure : ABBV-318

CAS No.: 1802848-94-7

 

ABBV-318

Catalog No.: URK-V2373  Only Used For Lab.

ABBV-318 is a potent small molecule Nav1.7/Nav1.8 blocker for the treatment of pain.

Biological Activity

ABBV-318 is a potent small molecule Nav1.7/Nav1.8 blocker for the treatment of pain. ABBV-318 also inhibited Nav1.8, another sodium channel isoform that is an active target for the development of new pain treatments.

Physicochemical Properties

References

1, Meena V Patel, Hillary M Peltier, Mark A Matulenko etc, al. Bioorg Med Chem. 2022 Jun1;63:116743.

URK-V2373-COA

URK-V2373-SDS

URK-V2373-TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• We are committed to providing our customers with exceptional support and service for all of our Membrane Transporter/Ion Channel Library products.
• We attach great importance to the accumulation and progress of technology, and continue to innovate ABBV-318 CAS No.: 1802848-94-7 that adapt to the development of the times.
• Our goal is to provide our customers with reliable Membrane Transporter/Ion Channel Library products and exceptional service.
• People-oriented and active innovation is the essence of our corporate culture. With high quality products and after-sales service, we have won the opportunity of long-term cooperation with many enterprises.
• We have a proven track record of providing high-quality Membrane Transporter/Ion Channel Library products to companies and individuals.
• We create value, mutual benefit and win-win with the concept of customer first, and take up the responsibility.
• Our Membrane Transporter/Ion Channel Library products are versatile and can be used in various research applications.
• Our company has established a sense of innovation and thinking, we use theoretical innovation to promote and guide system innovation and work innovation.
• We offer competitive pricing on all our Membrane Transporter/Ion Channel Library products, without compromising on quality.
• We make individuals and organizations grow together and build a broad stage for the development of talents.

Hot Tags: abbv-318 cas no.: 1802848-94-7, China abbv-318 cas no.: 1802848-94-7, epigenetic library for epigenetic induction, inhibitors for bioavailability, agonists for chemokine activation, inhibitors for cancer research, agonists for pharmacodynamics, nf b pathway glycomics